US 12,116,388 B2
Amylin receptor agonists
Cecilie Mia Joergensen, London (GB); Thomas Kruse, Herlev (DK); and Jesper F. Lau, Farum (DK)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Nov. 17, 2023, as Appl. No. 18/512,512.
Claims priority of application No. 22215958 (EP), filed on Dec. 22, 2022.
Prior Publication US 2024/0239852 A1, Jul. 18, 2024
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61P 3/04 (2006.01)
CPC C07K 14/4705 (2013.01) [A61P 3/04 (2018.01); A61K 38/00 (2013.01)] 15 Claims
 
1. An amylin receptor agonist according to Formula I (SEQ ID NO: 36):
AX2X3LX5TX7QTX10RLAEFLHHX19X20X21X22FGX25IX27X28X29TX31VGX34X35TX37,
wherein
X2 is S or G,
X3 is H, S, Q, or E,
X5 is S,
X7 is A,
X10 is Q or A,
X19 is S or absent,
X20 is S or absent,
X21 is D or absent,
X22 is N, P or absent,
X25 is A or P,
X27 is L or P,
X28 is S or P,
X29 is S or P,
X31 is D,
X34 is S or P,
X35 is N, D, or E, and
X37 is P.